Hippocampal Network Changes Following Mindfulness Training in Tobacco Vaping Adolescents in an Open-label, Pilot Study
Launched by NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) · Jul 15, 2024
Trial Information
Current as of November 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how mindfulness training might help teenagers who vape. Specifically, the researchers want to see if this training can change brain activity in a part of the brain called the hippocampus, which is involved in memory and learning. They hope that by improving brain function, teens will be able to reduce their vaping habits. The study is also exploring how easy it is to use a technology-based mindfulness program for young people.
To join the study, participants need to be between 13 and 18 years old and either be healthy non-vapers or teens who have vaped nicotine recently. They must be fluent in English, have permission from a parent or guardian if they are under 17, and have access to a smartphone for the program. Participants can expect to take part in mindfulness training and undergo brain scans to help researchers understand the effects of this training. It’s important to note that this study excludes individuals with certain medical conditions or those who practice regular meditation.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Non-Vaping group:
- • 1. For adolescents aged 17 and under, parental/guardian informed consent to participate in the study
- • 2. English language fluency
- • 3. Males and females; Age 13-18 enrolled in grades 9-12, or the summer after graduation.
- • 4. No MRI contraindications
- • 5. No evidence of current psychosis, mania, or significant suicidality
- • 6. If on medication for depression, anxiety or ADHD, dose has been stable for 3 months
- • 7. No DSM-5 diagnosis of moderate or severe SUD related to a psychoactive substance, including tobacco, in the past year
- • 8. Access to necessary resources for participating in a technology-based intervention, which includes smartphone ownership for this study
- • 9. No use of nicotine more than 5 times in their life, and none at all in the last 30 days prior to enrollment.
- Vaping group:
- • 1. For adolescents aged 17 and under, parental/guardian informed consent to participate in the study
- • 2. English language fluency
- • 3. Males and females; Age 13-18 enrolled in grades 9-12, or the summer after graduation.
- • 4. No MRI contraindications
- • 5. No evidence of current psychosis, mania, or significant suicidality
- • 6. If on medication for depression, anxiety or ADHD, dose has been stable for 3 months
- • 7. No DSM-5 diagnosis of moderate or severe SUD related to another psychoactive substance (other than tobacco) in the past year
- • 8. Vape a nicotine containing product at least 10 days in the past 30 days
- • 9. Access to necessary resources for participating in a technology-based intervention, which includes smartphone ownership for this study
- EXCLUSION CRITERIA:
- An individual who meets any of the following criteria will be excluded from participation in this study based on self and or parent-report unless otherwise noted:
- Vaping or Non-Vaping Group:
- • 1. Chronic medical conditions associated with cerebral blood flow abnormalities per PI/MAI determination after review of the medical history.
- • 2. Neurological conditions that may interfere with MRI data quality per PI/MAI determination after review of the medical history.
- • 3. Neurodevelopmental disorders that are likely to significantly affect data in the judgment of the MAI/PI
- • 4. Non-penetrating traumatic brain injury with loss of consciousness \> 30 minutes or significant sequalae persisting longer than 2 weeks or any penetrating traumatic brain injury.
- • 5. Changing dose of psychotropic medication in past 3 months
- • 6. Current regular meditation or yoga practice averaging \>10 min/day for \>2 days per week
- • 7. Pregnancy, self-report upon protocol entry, but by urine test prior to MRI scan.
About National Institute On Drug Abuse (Nida)
The National Institute on Drug Abuse (NIDA) is a leading federal agency within the U.S. Department of Health and Human Services, dedicated to advancing the understanding of drug abuse and addiction through rigorous scientific research. NIDA's mission encompasses the exploration of the biological, behavioral, and social aspects of substance use disorders, facilitating the development of effective prevention and treatment strategies. By funding and conducting innovative clinical trials, NIDA aims to translate research findings into practical solutions that improve public health and inform policy, ultimately contributing to the reduction of substance-related harm in communities across the nation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Betty Jo Salmeron, M.D.
Principal Investigator
National Institute on Drug Abuse (NIDA)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported